Telix Pharmaceuticals names David Gill as Board Chair
Gill succeeds Dr. Mark Nelson, who had served as interim Chair and will stay on the board as a Non-Executive Director.
Telix Pharmaceuticals Limited announced on September 1, 2026 that David Gill has been appointed Chair of the Board, effective immediately.1
Gill joined Telix as a Non-Executive Director in May 2026 as part of the company's board expansion and succession planning, with the intention that he would be appointed Chair in due course.1 He succeeds Dr. Mark Nelson, who has served as interim Chair and will remain on the Board as a Non-Executive Director.1
According to the announcement, Gill has spent more than 35 years in senior general management and financial leadership positions spanning commercial and clinical-stage biopharmaceutical companies, including work in radiopharmaceutical development, manufacturing and supply chain, as well as medical device firms, as the company describes him as a life sciences executive with over 35 years of experience in senior general management and financial leadership roles across commercial and clinical-stage biopharmaceutical and medical device companies.1
He currently sits on several other boards, as he currently serves on the boards of Evolus, Inc. (NASDAQ: EOLS), Allucent LLC, Bridge to Life Ltd, RapidPulse Inc., and huMannity Medtec.1
His prior executive roles include finance leadership at companies that were later acquired or renamed. Telix's filing states that Gill has served as Chief Financial Officer or President of multiple publicly traded companies, naming EndoChoice Holdings, Inc. (NYSE: GI), which was acquired by Boston Scientific, INC Research (NASDAQ: INCR), now known as Syneos Health, and CTI Molecular Imaging (NASDAQ: CTMI), which was acquired by Siemens.1 He holds a B.S. in Accounting from Wake Forest University and an MBA from Emory University.1
Telix Managing Director and Group CEO Dr. Christian Behrenbruch commented on the appointment, saying he was pleased to welcome Gill as Chair, citing his global life sciences leadership and financial expertise, and also thanked Nelson for his service as interim Chair, according to the release.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.